What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?-Reference-Cited by-同舟云学术

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Published:2016-12-02 Issue:1 Volume:2016 Page:648-649
ISSN:1520-4391
Container-title:Hematology
language:en
Short-container-title:

Author:

Janbain Maissaa¹,Pipe Steven²

Affiliation:

1. Section of Hematology and Medical Oncology, Department of Internal Medicine, Tulane School of Medicine, New Orleans, LA;

2. Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI

Abstract

Abstract A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/hematology/article-pdf/2016/1/648/1252314/hem088821.pdf

Reference12 articles.

1. Kasper CK . Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Montréal, Québec: World Federation of Hemophilia, September 2004. Treatment of Hemophilia Monograph Series. No. 34. Available at: http://www1.wfh.org/publication/files/pdf-1178.pdf. Accessed 27 September 2016.

2. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective;Oldenburg;Haemophilia,2014

3. New predictive approaches for ITI treatment;Minno;Haemophilia,2014

4. Immunogenicity of long-lasting recombinant factor VIII products;Ing;Cell Immunol,2016

5. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review;van Velzen;Br J Haematol,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective;Critical Reviews in Oncology/Hematology;2022-06

2. Immune tolerance induction experience from a single institute in the United Arab Emirates;Journal of Applied Hematology;2022

3. Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success;Haemophilia;2021-11-19

4. Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16;Frontiers in Immunology;2021-06-28

5. Recombinant factor VIII Fc for the treatment of haemophilia A;European Journal of Haematology;2021-03-31